LENSAR, Inc. (LNSR) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street mostly rises as Fed holds key rate steady, deferring next likely hike to December
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- Oracle sets $225 billion revenue target for FY30 at investor day
- S&P Global explores potential separation of Capital IQ business
- SpaceX stock drops amid spaceport lawsuit, debt concerns
- Rivian shares slip ahead of Thursday earnings release
- Moderna stock rises on latest cancer vaccine data publication
LENSAR Reports First Quarter 2022 Financial Results and Provides Business Update
May 9, 2022 7:00 AM EDTFirst Quarter Revenue Increases 33% Over 2021 Levels
First Quarter Procedure Volume Increases 38% Over 2021 Levels
ORLANDO, Fla.--(BUSINESS WIRE)-- LENSAR, Inc. (Nasdaq: LNSR) (LENSAR or the Company), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2022 and provided an update on operational initiatives.
We have started 2022 on an impressive note by achieving more than 30% growth in both revenue and worldwide procedure volumes as compared to the first... More



